A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge

Abstract

The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.

References 22

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.
   Nasal Delivery of an Adenovirus-Based Vaccine Bypasses Pre-Existing Immunity to the Vaccine Carrier and Improves the Immune Response in Mice · 2008

   No notice
3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

9. 9.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

16. 16.
    Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2 · 2020

    No notice
17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

18. 18.
    Development of an inactivated vaccine candidate for SARS-CoV-2 · 2020

    No notice
19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

20. 20.
    DNA vaccine protection against SARS-CoV-2 in rhesus macaques · 2020

    No notice
21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 8

• A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies · 2022
  No notice
• SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants · 2021
  No notice
• Coronaviruses Associated with the Superfamily <i>Musteloidea</i> · 2021
  Not checked
• Current progress and challenges in the design and development of a successful COVID-19 vaccine · 2021
  Not checked
• Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19 · 2021
  No notice
• SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates · 2021
  No notice
• Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications · 2021
  No notice
• Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.